West Pharmaceutical Services, Inc. (WST)
339.97
-2.76
(-0.81%)
USD |
NYSE |
Sep 04, 16:00
339.89
-0.08
(-0.02%)
After-Hours: 20:00
West Pharmaceutical Services Research and Development Expense (Quarterly) : 19.70M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.70M |
| March 31, 2026 | 15.80M |
| December 31, 2025 | 21.80M |
| September 30, 2025 | 17.10M |
| June 30, 2025 | 19.10M |
| March 31, 2025 | 16.30M |
| December 31, 2024 | 18.50M |
| September 30, 2024 | 15.50M |
| June 30, 2024 | 17.50M |
| March 31, 2024 | 17.60M |
| December 31, 2023 | 18.40M |
| September 30, 2023 | 16.40M |
| June 30, 2023 | 16.50M |
| March 31, 2023 | 17.10M |
| December 31, 2022 | 15.90M |
| September 30, 2022 | 13.60M |
| June 30, 2022 | 14.40M |
| March 31, 2022 | 14.60M |
| December 31, 2021 | 13.70M |
| September 30, 2021 | 13.10M |
| June 30, 2021 | 13.80M |
| March 31, 2021 | 12.20M |
| December 31, 2020 | 12.90M |
| September 30, 2020 | 12.50M |
| June 30, 2020 | 10.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.70M |
| December 31, 2019 | 10.20M |
| September 30, 2019 | 9.30M |
| June 30, 2019 | 9.60M |
| March 31, 2019 | 9.80M |
| December 31, 2018 | 9.80M |
| September 30, 2018 | 10.10M |
| June 30, 2018 | 10.80M |
| March 31, 2018 | 9.60M |
| December 31, 2017 | 9.70M |
| September 30, 2017 | 9.10M |
| June 30, 2017 | 10.00M |
| March 31, 2017 | 10.30M |
| December 31, 2016 | 9.60M |
| September 30, 2016 | 9.00M |
| June 30, 2016 | 8.80M |
| March 31, 2016 | 9.40M |
| December 31, 2015 | 10.00M |
| September 30, 2015 | 8.50M |
| June 30, 2015 | 8.10M |
| March 31, 2015 | 7.50M |
| December 31, 2014 | 7.80M |
| September 30, 2014 | 9.60M |
| June 30, 2014 | 9.90M |
| March 31, 2014 | 10.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Globus Medical, Inc. | 36.32M |
| Hinge Health, Inc. | 34.06M |
| Baxter International, Inc. | 125.00M |
| The Cooper Cos., Inc. | 42.50M |
| Becton, Dickinson & Co. | 258.00M |